Become A Featured Company

Psychedelics Production Challenges & Solutions

Ryan Allway

December 21st, 2020

App, Exclusive, Psychedelics, Top News

Psilocybin and other tryptamine-based compounds could become blockbuster therapeutics for the treatment of depression, post-traumatic stress disorder and other difficult to treat psychiatric conditions. While many clinical trials are underway, researchers are turning their attention toward the problem of mass-producing psychedelics in a cost-effective way.

Let’s take a look at some of the production challenges associated with psychedelics, as well as how companies like CB Therapeutics Inc. are developing scalable solutions. 

Production Challenges

Psilocybin has become the most popular psychedelic substance but isolating the substance from magic mushrooms is expensive and variable. For example, the most common magic mushroom contains between 10 and 12 milligrams of psilocybin per gram of dried mushroom whereas an effective oral dose requires between six and 20 milligrams.

Mescaline is another prime example of a production issue. With the decriminalization of psychedelics in several U.S. cities, demand for mescaline cacti has soared and overharvesting has become a major problem. The plant takes decades to regenerate and produce fruit, which has created problems for Mexican Indians and Native Americans that rely on the plant.

In addition to raw production, quality control is another important issue facing the industry. Relying on growing and harvesting fungi means that researchers and practitioners must trust that a standardized process was used. The cannabis industry serves as a reminder that production methods aren’t always as clean as one would hope.

Click here to learn more about investing in scalable psychedelic production

Scalable Solutions

Many biotech and pharmaceutical companies have been exploring alternative ways to produce psilocybin. Unfortunately, many of these chemical-based techniques require expensive components in the process, which translates to higher costs per gram.

CB Therapeutics Inc. has developed an enzyme-based process that could be substantially more efficient than existing chemical and biosynthesis techniques. In addition to making the active compounds that occur naturally, the enzymatic processes are capable of yielding bioidentical compounds as well as their analogs for targeting therapeutics.

“We continue to advance our research and development for the cost-effective and highly scalable biosynthetic production of these compounds,” said Dr. Jacob Vogan, Chief Science Officer of CB Therapeutics in a recent press release. “There is unmatched potential for generating both well-known compounds such as psilocybin and 5-MeO-DMT and also analogs with unique characteristics using our cellular agriculture platform. We look forward to manufacturing these molecules to further our mission to treat depressive disorders and addiction as an adjunct to psychotherapy.”  

In June, the company announced the successful biosynthesis of DMT and related tryptamine compounds in yeast and filed a patent covering the process. The company’s goal is to leverage the production process to support clinical trials for these compounds as therapeutics, and ultimately, support their commercialization on a much larger scale, if approved by the FDA.

Click here to learn more about investing in scalable psychedelic production

Looking Ahead

CB Therapeutics Inc. is uniquely positioned to supply the psychedelics industry—both in a research role and a commercial production role. In combination with its cannabinoid production capabilities, investors may want to take a closer look at the company over the coming months as it continues to expand its capabilities and build its IP portfolio.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading